Camille, A.; Christophe, W.; Oliver, G.; Martin, W.P.; Roberto, C.; Georg, N.; Patric, B.
Clinical Value of Soluble Suppression of Tumourigenicity 2 (sST2) in Addition to NTproBNP Measurements in a General Cardiac Outpatient Population. Cardiovasc. Med. 2021, 24, w10045.
https://doi.org/10.4414/cvm.2021.02141
AMA Style
Camille A, Christophe W, Oliver G, Martin WP, Roberto C, Georg N, Patric B.
Clinical Value of Soluble Suppression of Tumourigenicity 2 (sST2) in Addition to NTproBNP Measurements in a General Cardiac Outpatient Population. Cardiovascular Medicine. 2021; 24(1):w10045.
https://doi.org/10.4414/cvm.2021.02141
Chicago/Turabian Style
Camille, Ammann, Wyss Christophe, Gämperli Oliver, Wenaweser Peter Martin, Corti Roberto, Noll Georg, and Biaggi Patric.
2021. "Clinical Value of Soluble Suppression of Tumourigenicity 2 (sST2) in Addition to NTproBNP Measurements in a General Cardiac Outpatient Population" Cardiovascular Medicine 24, no. 1: w10045.
https://doi.org/10.4414/cvm.2021.02141
APA Style
Camille, A., Christophe, W., Oliver, G., Martin, W. P., Roberto, C., Georg, N., & Patric, B.
(2021). Clinical Value of Soluble Suppression of Tumourigenicity 2 (sST2) in Addition to NTproBNP Measurements in a General Cardiac Outpatient Population. Cardiovascular Medicine, 24(1), w10045.
https://doi.org/10.4414/cvm.2021.02141
